High serum interleukin‐34 level is a predictor of poor prognosis in patients with non‐viral hepatocellular carcinoma

We aimed to investigate the impact of interleukin (IL)‐34 and YKL‐40, regulators of hepatic fibrosis and tumor growth, on the prognosis of patients with non‐viral hepatocellular carcinoma (HCC).

[1]  T. Kawaguchi,et al.  Prognostic profile of patients with non-viral hepatocellular carcinoma: A comparative study with hepatitis C virus-related hepatocellular carcinoma using data mining analysis. , 2019, Oncology letters.

[2]  H. Yoshiji,et al.  A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011–2015 update , 2018, Journal of Gastroenterology.

[3]  T. Saibara,et al.  A Data Mining-based Prognostic Algorithm for NAFLD-related Hepatoma Patients: A Nationwide Study by the Japan Study Group of NAFLD , 2018, Scientific Reports.

[4]  K. Chayama,et al.  Wisteria floribunda agglutinin‐positive Mac‐2 binding protein predicts the development of hepatocellular carcinoma in patients with non‐alcoholic fatty liver disease , 2018, Hepatology research : the official journal of the Japan Society of Hepatology.

[5]  Jun Ye,et al.  Serum interleukin-34 level can be an indicator of liver fibrosis in patients with chronic hepatitis B virus infection , 2018, World journal of gastroenterology.

[6]  Muhammad Baghdadi,et al.  Enhanced IL-34 expression in Nivolumab-resistant metastatic melanoma , 2018, Inflammation and regeneration.

[7]  Y. Miyagi,et al.  High co-expression of IL-34 and M-CSF correlates with tumor progression and poor survival in lung cancers , 2018, Scientific Reports.

[8]  M. Kudo,et al.  Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update , 2017, Hepatology International.

[9]  I. Anegon,et al.  Immunoregulatory properties of the cytokine IL-34 , 2017, Cellular and Molecular Life Sciences.

[10]  Yu-Ling Wang,et al.  Overexpression of YKL-40 Predicts Poor Prognosis in Patients Undergoing Curative Resection of Pancreatic Cancer , 2017, Pancreas.

[11]  W. Ge,et al.  Elevated YKL-40 expression is associated with a poor prognosis in breast cancer patients , 2016, Oncotarget.

[12]  Wira Eka Putra,et al.  Chemotherapy-Induced IL34 Enhances Immunosuppression by Tumor-Associated Macrophages and Mediates Survival of Chemoresistant Lung Cancer Cells. , 2016, Cancer research.

[13]  K. Chayama,et al.  Serum YKL-40 as a marker of liver fibrosis in patients with non-alcoholic fatty liver disease , 2016, Scientific Reports.

[14]  Austin Miller,et al.  PD-1+ and Foxp3+ T cell reduction correlates with survival of HCC patients after sorafenib therapy. , 2016, JCI insight.

[15]  K. Chayama,et al.  Interleukin-34 as a fibroblast-derived marker of liver fibrosis in patients with non-alcoholic fatty liver disease , 2016, Scientific Reports.

[16]  Ya Cao,et al.  miR‐28‐5p‐IL‐34‐macrophage feedback loop modulates hepatocellular carcinoma metastasis , 2016, Hepatology.

[17]  S. Wongkham,et al.  YKL-40/chitinase-3-like protein 1 is associated with poor prognosis and promotes cell growth and migration of cholangiocarcinoma , 2016, Tumor Biology.

[18]  Jiang-feng Xu,et al.  PIVKA-II is an independent prognostic factor for overall survival of HCC patients and maybe associated with epithelial-mesenchymal transition. , 2015, Journal of hepatology.

[19]  D. Heymann,et al.  Interleukin‐34 promotes tumor progression and metastatic process in osteosarcoma through induction of angiogenesis and macrophage recruitment , 2015, International journal of cancer.

[20]  Jianbo He,et al.  miR-128-3p suppresses hepatocellular carcinoma proliferation by regulating PIK3R1 and is correlated with the prognosis of HCC patients. , 2015, Oncology reports.

[21]  R. Schwabe,et al.  Hepatic inflammation and fibrosis: Functional links and key pathways , 2015, Hepatology.

[22]  S. Kawasaki,et al.  Evidence‐based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH‐HCC Guidelines) , 2015, Hepatology research : the official journal of the Japan Society of Hepatology.

[23]  P. Roingeard,et al.  IL‐34 and macrophage colony‐stimulating factor are overexpressed in hepatitis C virus fibrosis and induce profibrotic macrophages that promote collagen synthesis by hepatic stellate cells , 2014, Hepatology.

[24]  Y. Imai,et al.  JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan , 2014, Liver Cancer.

[25]  T. Kawaguchi,et al.  Serum albumin level is a notable profiling factor for non‐B, non‐C hepatitis virus‐related hepatocellular carcinoma: A data‐mining analysis , 2014, Hepatology research : the official journal of the Japan Society of Hepatology.

[26]  P. Galle,et al.  HCC therapies—lessons learned , 2014, Nature Reviews Gastroenterology &Hepatology.

[27]  N. Hayashi,et al.  Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multicenter cohort study , 2014, Journal of Gastroenterology.

[28]  H. Park,et al.  IL-34 is associated with obesity, chronic inflammation, and insulin resistance. , 2014, The Journal of clinical endocrinology and metabolism.

[29]  M. Makuuchi,et al.  Nationwide Study of 4741 Patients With Non-B Non-C Hepatocellular Carcinoma With Special Reference to the Therapeutic Impact , 2014, Annals of surgery.

[30]  D. Amadori,et al.  miR-126 and miR-126* repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis , 2013, Nature Cell Biology.

[31]  Li-li Chen,et al.  Elevated Serum YKL-40 Level Predicts Poor Prognosis in Hepatocellular Carcinoma After Surgery , 2012, Annals of surgical oncology.

[32]  M. Sata,et al.  The incidence of hepatocellular carcinoma associated with hepatitis C infection decreased in Kyushu area , 2011, Medical science monitor : international medical journal of experimental and clinical research.

[33]  Y. Aizawa,et al.  Etiology of non-B non-C hepatocellular carcinoma in the eastern district of Tokyo , 2008, Journal of Gastroenterology.

[34]  J. Montaner,et al.  Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection , 2006, Hepatology.

[35]  Liver Cancer Study Group of Japan.  The general rules for the clinical and pathological study of primary liver cancer , 2006, The Japanese journal of surgery.

[36]  P. Kristjansen,et al.  Expression of YKL-40 by peritumoral macrophages in human small cell lung cancer. , 2005, Lung cancer.

[37]  H. Nielsen,et al.  Serum YKL-40 and colorectal cancer , 1999, British Journal of Cancer.

[38]  J. Johansen,et al.  Identification of proteins secreted by human osteoblastic cells in culture , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.